Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• Prostate cancer (CaP) screening relies on prostate-specific antigen (PSA) and digital rectal examination.
• While PSA screening reduces CaP-specific mortality, it has limitations including unnecessary biopsies and overdiagnosis of indolent cancers.
• CaP is a leading cause of cancer death in Western countries, necessitating effective screening.

Purpose of the Study:

• To explore the use of PSA derivatives, specifically PSA kinetics, to enhance the specificity of prostate cancer screening.
• To minimize the risks of unnecessary prostate biopsies and the overdiagnosis of clinically insignificant CaP.
• To improve the selection of men who would benefit from prostate cancer screening and intervention.

Main Methods:

• Analysis of PSA kinetics as a biomarker for prostate cancer.
• Evaluation of PSA derivatives to improve diagnostic accuracy.
• Review of existing prostate cancer screening protocols and their limitations.

Main Results:

• PSA kinetics show potential for increasing specificity in detecting clinically relevant prostate cancer.
• Improved specificity could reduce the rate of unnecessary prostate biopsies.
• Early diagnosis of significant CaP allows for timely treatment or surveillance decisions.

Conclusions:

• PSA kinetics represent a promising approach to refine prostate cancer screening protocols.
• Utilizing PSA kinetics can help differentiate between indolent and aggressive forms of CaP.
• This strategy aims to balance the benefits of early detection with the avoidance of overtreatment.